Exelixis (NASDAQ:EXEL) Given Buy Rating at Truist Financial

Exelixis (NASDAQ:EXEL - Get Free Report)'s stock had its "buy" rating reissued by equities research analysts at Truist Financial in a research report issued on Monday,Benzinga reports. They currently have a $55.00 price target on the biotechnology company's stock, up from their previous price target of $43.00. Truist Financial's price target suggests a potential upside of 25.15% from the company's current price.

Several other equities analysts have also issued reports on the company. Morgan Stanley reiterated an "overweight" rating and issued a $47.00 target price (up previously from $40.00) on shares of Exelixis in a research note on Wednesday, May 14th. JMP Securities lifted their price objective on shares of Exelixis from $47.00 to $50.00 and gave the stock a "market outperform" rating in a research report on Monday. Stifel Nicolaus increased their target price on shares of Exelixis from $36.00 to $38.00 and gave the company a "hold" rating in a research report on Wednesday, May 14th. Guggenheim set a $45.00 target price on shares of Exelixis and gave the company a "buy" rating in a research note on Thursday, May 15th. Finally, UBS Group reaffirmed an "underperform" rating on shares of Exelixis in a research report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating and twelve have given a buy rating to the company's stock. According to data from MarketBeat, Exelixis currently has a consensus rating of "Moderate Buy" and a consensus price target of $41.00.

Exelixis Stock Up 8.9%

EXEL stock traded up $3.58 during trading on Monday, hitting $43.95. 5,941,774 shares of the company's stock traded hands, compared to its average volume of 2,391,665. The business has a fifty day simple moving average of $40.30 and a two-hundred day simple moving average of $37.06. The firm has a market capitalization of $11.98 billion, a P/E ratio of 19.96, a PEG ratio of 0.82 and a beta of 0.28. Exelixis has a 1 year low of $21.82 and a 1 year high of $51.89.

Insider Activity at Exelixis

In other Exelixis news, EVP Dana Aftab sold 1,508 shares of the company's stock in a transaction on Thursday, May 1st. The shares were sold at an average price of $39.00, for a total value of $58,812.00. Following the sale, the executive vice president now directly owns 693,181 shares of the company's stock, valued at approximately $27,034,059. This represents a 0.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Patrick J. Haley sold 126,383 shares of Exelixis stock in a transaction dated Thursday, May 15th. The shares were sold at an average price of $47.96, for a total value of $6,061,328.68. Following the transaction, the executive vice president now owns 446,459 shares of the company's stock, valued at $21,412,173.64. The trade was a 22.06% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 458,113 shares of company stock worth $21,024,817 over the last quarter. Insiders own 2.85% of the company's stock.

Institutional Investors Weigh In On Exelixis

Several hedge funds have recently bought and sold shares of the stock. Coppell Advisory Solutions LLC purchased a new stake in Exelixis during the fourth quarter worth $25,000. Hemington Wealth Management raised its position in shares of Exelixis by 211.3% in the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 522 shares during the period. Colonial Trust Co SC boosted its stake in shares of Exelixis by 616.9% during the 4th quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 765 shares in the last quarter. Principal Securities Inc. grew its position in shares of Exelixis by 62.8% during the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company's stock valued at $32,000 after acquiring an additional 373 shares during the period. Finally, Bartlett & CO. Wealth Management LLC acquired a new stake in shares of Exelixis during the 1st quarter valued at about $37,000. Hedge funds and other institutional investors own 85.27% of the company's stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.